Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab
Authors
Keywords
Antibody(s), Antibody drug(s), IgG antibody(s), Interspecies (dose) scaling, Monoclonal antibody(s), Pharmacodynamics, Pharmacokinetics
Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-12-23
DOI
10.1016/j.xphs.2021.12.019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
- (2020) Cris Kamperschroer et al. Journal of Immunotoxicology
- CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
- (2019) Ji Li et al. Science Translational Medicine
- Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis
- (2019) Thomas E. Kraft et al. mAbs
- CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies
- (2018) Marina Bacac et al. CLINICAL CANCER RESEARCH
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment
- (2017) Frank R. Brennan et al. mAbs
- Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
- (2017) Miroslav Dostalek et al. mAbs
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
- (2017) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans
- (2017) Elisabeth Husar et al. TOXICOLOGIC PATHOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically Engineered Humanized Mouse Models for Preclinical Antibody Studies
- (2013) Gabriele Proetzel et al. BIODRUGS
- Challenges and approaches for the development of safer immunomodulatory biologics
- (2013) Jean G. Sathish et al. NATURE REVIEWS DRUG DISCOVERY
- After TGN1412: Recent developments in cytokine release assays
- (2012) R. Stebbings et al. Journal of Immunotoxicology
- A strategy for risk mitigation of antibodies with fast clearance
- (2012) Isidro Hötzel et al. mAbs
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans
- (2012) Yan Xin et al. PHARMACEUTICAL RESEARCH
- Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data
- (2011) Masataka Oitate et al. Drug Metabolism and Pharmacokinetics
- Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data
- (2011) Rong Deng et al. mAbs
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started